CHUV

Molecular Partners Confirms Retained Activity of Ensovibep on the Positions Mutated in Emerging Omicron Variant of SARS-CoV-2 In Vitro

Retrieved on: 
Tuesday, November 30, 2021
Patient, Private Securities Litigation Reform Act, Security (finance), Humanitarian use licenses, U.S. Securities and Exchange Commission, Ophthalmology, CEO, Molecular Partners, Risk, NIH, Company, LR, Novartis, Hospital, Form, Partnership, Severe acute respiratory syndrome coronavirus 2, Clinical trial, SEC, Mall of America, Investor, Therapy, COVID-19, National, Twitter, Mutation, GLOBE, CHUV, Marketing, Partner, DARPin, Molecule, Infection, Vaccine, Pharmaceutical industry

The Omicron strain contains 32 new mutations compared to the wild-type strain originally identified in Wuhan, China.

Key Points: 
  • The Omicron strain contains 32 new mutations compared to the wild-type strain originally identified in Wuhan, China.
  • Based on previous studies, ensovibep, a tri-specific antiviral targeting the spike protein of SARS-CoV-2, maintains full potency against the individual positions of relevance to ensovibep that are mutated in the Omicron variant.
  • To date, ensovibep has maintained activity in vitro against all variants of concern detected, including the Delta strain2.
  • Molecular Partners collaboration partner, Novartis, is conducting the clinical trial for ensovibep, with Molecular Partners as a sponsor.

MindMaze Announces Kevin J. Gallagher as Chief Financial Officer Amid Significant Company Growth

Retrieved on: 
Wednesday, November 17, 2021
Patient, EMEA, CEO, Johns Hopkins School of Medicine, Neuroscience, Workforce, Capital market, CE, Lausanne University Hospital, Company, Single-frequency network, University of California, San Francisco, Health, Neuro, Industry, Swiss Federal Institute of Aquatic Science and Technology, Thomas Weisel Partners, University, Spinal cord, Solution, Unicorn, Therapy, Lists of diseases, Alzheimer's disease, ICM, UCSF, EPFL, Institute, UBS, Citigroup, CHUV, Patent, Mount Sinai Health System, Artificial intelligence, Neurology, Neurological disorder, Medical tourism, FDA, Health technology, Parkinson's disease, Engineering, Growth, Encarta, Multimedia, In re Citigroup Inc. Shareholder Derivative Litigation, Stroke, Swiss Federal Institute of Technology, Pharmaceutical industry, Medical imaging

"MindMaze is at a pivotal growth point and we could not be more thrilled to welcome Kevin to our executive team.

Key Points: 
  • "MindMaze is at a pivotal growth point and we could not be more thrilled to welcome Kevin to our executive team.
  • "Kevin is a key addition to the MindMaze team and reflects the rapid growth and development that we are experiencing as we expand our workforce and actively recruit across geographies and functions."
  • "I am excited to be joining MindMaze and look forward to driving growth and building value for all of our partners," said Mr. Gallagher.
  • I am thrilled to be joining the tremendously talented and passionate MindMaze team at this pivotal time for the Company."

MindMaze Announces Kevin J. Gallagher as Chief Financial Officer Amid Significant Company Growth

Retrieved on: 
Wednesday, November 17, 2021
Patient, EMEA, CEO, Johns Hopkins School of Medicine, Neuroscience, Workforce, Capital market, CE, Lausanne University Hospital, Company, Single-frequency network, University of California, San Francisco, Health, Neuro, Industry, Swiss Federal Institute of Aquatic Science and Technology, Thomas Weisel Partners, University, Spinal cord, Solution, Unicorn, Therapy, Lists of diseases, Alzheimer's disease, ICM, UCSF, EPFL, Institute, UBS, Citigroup, CHUV, Patent, Mount Sinai Health System, Artificial intelligence, Neurology, Neurological disorder, Medical tourism, FDA, Health technology, Parkinson's disease, Engineering, Growth, Encarta, In re Citigroup Inc. Shareholder Derivative Litigation, Stroke, Swiss Federal Institute of Technology, Pharmaceutical industry, Medical imaging

"MindMaze is at a pivotal growth point and we could not be more thrilled to welcome Kevin to our executive team.

Key Points: 
  • "MindMaze is at a pivotal growth point and we could not be more thrilled to welcome Kevin to our executive team.
  • "Kevin is a key addition to the MindMaze team and reflects the rapid growth and development that we are experiencing as we expand our workforce and actively recruit across geographies and functions."
  • "I am excited to be joining MindMaze and look forward to driving growth and building value for all of our partners," said Mr. Gallagher.
  • I am thrilled to be joining the tremendously talented and passionate MindMaze team at this pivotal time for the Company."

RayStation in clinical use with CyberKnife at Centre hospitalier universitare vaudois (CHUV) in Switzerland

Retrieved on: 
Thursday, September 30, 2021
Achievement, RaySearch Laboratories, Workflow, Center, Patient, Hospital, CEO, Radiation, Organization, CHUV, TPS, Industry, Cyberknife, Medical device, Pharmaceutical industry

STOCKHOLM, Sept. 30, 2021 /PRNewswire/ -- RaySearch Laboratories AB (publ) announces that Centre hospitalier universitaire vaudois (CHUV) in Lausanne, Switzerland, is the first center in the world to treat a patient using the RayStation* treatment planning system in combination with Accuray CyberKnifetreatment delivery system.

Key Points: 
  • STOCKHOLM, Sept. 30, 2021 /PRNewswire/ -- RaySearch Laboratories AB (publ) announces that Centre hospitalier universitaire vaudois (CHUV) in Lausanne, Switzerland, is the first center in the world to treat a patient using the RayStation* treatment planning system in combination with Accuray CyberKnifetreatment delivery system.
  • The RayStation module for CyberKnife planning provides support for optimization with the three different collimation types fixed cones, Iris Variable Aperture and Incise Multileaf Collimator and all CyberKnife tracking techniques for Synchronyreal-time motion synchronization.
  • In June 2021, the relationship with the clinic was extended as CHUV ordered additional RayStation functionality for automated treatment planning and segmentation using machine learning techniques and support for CyberKnife planning.
  • We are impressed by how fast the system was brought into clinical use, as the added functionality for RayStation was ordered as late as June this year.